根据心力衰竭的基线铁动力学与保存的喷射分数的运动训练反应:TRAINING-HF试验的子研究
Patricia Palau1, Laura López1,2, Eloy Domínguez1,3
1Department of Cardiology, Hospital Clínico Universitario, INCLIVA. Universitat de València, Valencia, Spain.
缺铁 (ID) 在心力衰竭与保存的喷射分数 (HFpEF) 患者损害功能能力. 在ID的HFpEF患者中,物理治疗的益处降低了,这突显了铁动力学的重要性.
科学领域:
- 心脏病学 心脏病学
- 运动生理学 运动生理学
- 营养科学 营养科学
背景情况:
- 缺铁 (ID) 与心力衰竭 (HF) 患者的功能能力降低有关,包括那些有保存喷射分数 (HFpEF) 患者.
- 了解铁状况对治疗反应的影响对于优化HFpEF护理至关重要.
研究的目的:
- 为了研究基线铁状况 (铁动力学) 如何影响稳定HFpEF患者12周物理治疗计划后峰值氧耗 (峰值VO2) 的改善.
- 分析不同物理治疗干预和铁动力学对有氧能力的相互作用.
主要方法:
- 一个随机临床试验的后期分析,涉及59名稳定的HFpEF患者.
- 患者接受了12周的启发性肌肉训练 (IMT),功能电刺激 (FES),IMT+FES组合或常规护理 (UC).
- 评估了基线血清费里和转激素和度 (TSAT),以确定ID. 线性混合回归模型分析了VO2.0峰值的变化.
主要成果:
- 在59名参与者中,有61%的人患有ID. 与常规护理相比,患有ID,较低费里或较低TSAT的患者在活性疗法下,高峰VO2的改善较小.
- 在铁动力学状态和在VO2.2峰值上积极物理治疗干预措施的有效性之间观察到显著的相互作用 (P<0.001).
结论:
- 基线铁动力学显著改变了HFpEF患者对物理疗法的反应.
- 铁状况是影响提高有氧能力的关键因素,以应对HFpEF的运动干预措施.
更多相关视频
07:40Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training
Published on: October 10, 2019
12:37Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
Published on: February 9, 2016
相关概念视频
Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Exercise and Cardiac Output
Sustained exercise increases the muscles' oxygen demand, which can be...
Pathophysiology of Heart Failure
Exercise and Muscle Performance
Endurance exercises
Endurance exercises involve running, swimming, or cycling, which require repetitive movements with low force output. When a person engages in endurance exercise, a few noticeable changes occur in their skeletal muscles. For instance, the number of capillaries...
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
